Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 19 September

Grady Wulff
September 19, 2022

Weekly Wrap 16 September

Grady Wulff
September 16, 2022

Morning Bell 16 September

Sophia Mavridis
September 16, 2022

Morning Bell 15 September

Sophia Mavridis
September 15, 2022

Closing Bell 14 September

Grady Wulff
September 14, 2022

Morning Bell 14 September

Grady Wulff
September 14, 2022

Closing Bell 13 September

Grady Wulff
September 13, 2022

Morning Bell 13 September

Paulina Peters
September 13, 2022

Closing Bell 12 September

Grady Wulff
September 12, 2022

Morning Bell 12 September

Grady Wulff
September 12, 2022

Weekly Wrap 9 September

Grady Wulff
September 9, 2022

Morning Bell 9 September

Sophia Mavridis
September 9, 2022